Document text
FDA-CBER-2021-5683-0950948
FDA-CBER-2021-5683-0950949
FDA-CBER-2021-5683-0950950
FDA-CBER-2021-5683-0950951
FDA-CBER-2021-5683-0950952
FDA-CBER-2021-5683-0950953
FDA-CBER-2021-5683-0950954
FDA-CBER-2021-5683-0950955
FDA-CBER-2021-5683-0950956
FDA-CBER-2021-5683-0950957
FDA-CBER-2021-5683-0950958
FDA-CBER-2021-5683-0950959
FDA-CBER-2021-5683-0950960
FDA-CBER-2021-5683-0950961
FDA-CBER-2021-5683-0950962
FDA-CBER-2021-5683-0950963
FDA-CBER-2021-5683-0950964
• are immunocompromised or are on a medicine that affects your
immune system
• are pregnant, plan to become pregnant, or are breastfeeding
• have received another COVID -19 vaccine
• have ever fainted in association with an injection
The vaccine may not prote ct everyone.
Side effects reported with the vaccine include:
• There is a remote chance that the vaccine could cause a severe allergic
reaction
o A severe allergic reaction would usually occur within a few
minutes to one hour after getting a dose of the v accine. For this
reason, your vaccination provider may ask you to stay at the
place where you received your vaccine for monitoring after
vaccination
o Signs of a severe allergic reaction can include difficulty
breathing, swelling of your face and throat, a fast heartbeat, a
bad rash all over your body, dizziness, and weakness
o If you experience a severe allergic reaction, call 9 -1-1 or go to
the nearest hospita l
• Myocarditis (inflammation of the heart muscle) and pericarditis
(inflammation of the lining outside the heart) have occurred in some
people who have received the vaccine. In most of these people,
symptoms began within a few days following receipt of the second
dose of the vaccine. The chance of having this occur is very low. You
should seek medical attention right away if you have any of the
following symptoms after receiving the vaccine:
o chest pain
o shortness of breath
o feelings of having a fast -beating, f luttering, or pounding heart
• Side effects that have been reported with the vaccine include:
o severe allergic reactions; non -severe allergic reactions such as
rash, itching, hives, or swelling of the face; myocarditis
FDA-CBER-2021-5683-0950965
FDA-CBER-2021-5683-0950966
immunocompromise
The Pfizer -BioNTech COVID -19 Vaccine has received EUA from FDA to:
• prevent COVID -19 in individuals 12 years of age and older, a nd
• provide a third dose to individuals 12 years of age and older who have
been determined to have certain kinds of immunocompromise
The FDA -approved COMIRNATY® (COVID -19 Vaccine, mRNA) and the EUA -
authorized Pfizer -BioNTech COVID -19 Vaccine have the same f ormulation
and can be used interchangeably to provide the COVID -19 vaccination
series. An individual may be offered either COMIRNATY® (COVID -19 Vaccine,
mRNA) or the Pfizer -BioNTech COVID -19 Vaccine to prevent coronavirus
disease 2019 (COVID -19) caused by SARS -CoV-2.
The emergency use of the product has not been approved or licensed by
FDA, but has been authorized by FDA, under an Emergency Use
Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID -19) for use
in individuals 12 years of age and olde r; and the emergency use of this
product is only authorized for the duration of the declaration that
circumstances exist justifying the authorization of emergency use of the
medical product under Section 564(b)(1) of the FD&C Act unless the
declaration is terminated or authorization revoked sooner. For these
authorized uses, the vaccine has not been approved or licensed.
Please do not respond to this e -mail. This informational email was sent to
you in response to your friend’s request. Your personal informa tion has not
been stored and your e -mail address will not be shared with any third
parties. You have not been signed up to receive further information. If you
would like to sign -up, please visit Comirnaty.com . If you would like to get in
touch with Pfizer, visit the Contact Us page or call 1-800-879-3477 .
View the Pfizer Privacy Policy here .
Pfizer
P.O. Box 29387
FDA-CBER-2021-5683-0950967
FDA-CBER-2021-5683-0950968
FDA-CBER-2021-5683-0950969
FDA-CBER-2021-5683-0950970
FDA-CBER-2021-5683-0950971
FDA-CBER-2021-5683-0950972
FDA-CBER-2021-5683-0950973
FDA-CBER-2021-5683-0950974
FDA-CBER-2021-5683-0950975
FDA-CBER-2021-5683-0950976
FDA-CBER-2021-5683-0950977
FDA-CBER-2021-5683-0950978
FDA-CBER-2021-5683-0950979
FDA-CBER-2021-5683-0950980
FDA-CBER-2021-5683-0950981
FDA-CBER-2021-5683-0950982
FDA-CBER-2021-5683-0950983
FDA-CBER-2021-5683-0950984
FDA-CBER-2021-5683-0950985
FDA-CBER-2021-5683-0950986
FDA-CBER-2021-5683-0950987
FDA-CBER-2021-5683-0950988
FDA-CBER-2021-5683-0950989
FDA-CBER-2021-5683-0950990
FDA-CBER-2021-5683-0950991
FDA-CBER-2021-5683-0950992
FDA-CBER-2021-5683-0950993
FDA-CBER-2021-5683-0950994
FDA-CBER-2021-5683-0950995
FDA-CBER-2021-5683-0950996
FDA-CBER-2021-5683-0950997
FDA-CBER-2021-5683-0950998
FDA-CBER-2021-5683-0950999
FDA-CBER-2021-5683-0951000
FDA-CBER-2021-5683-0951001
FDA-CBER-2021-5683-0951002
FDA-CBER-2021-5683-0951003
FDA-CBER-2021-5683-0951004
FDA-CBER-2021-5683-0951005
FDA-CBER-2021-5683-0951006
FDA-CBER-2021-5683-0951007
FDA-CBER-2021-5683-0951008
FDA-CBER-2021-5683-0951009
FDA-CBER-2021-5683-0951010
FDA-CBER-2021-5683-0951011
FDA-CBER-2021-5683-0951012
FDA-CBER-2021-5683-0951013
FDA-CBER-2021-5683-0951014
FDA-CBER-2021-5683-0951015
FDA-CBER-2021-5683-0951016
FDA-CBER-2021-5683-0951017
FDA-CBER-2021-5683-0951018
FDA-CBER-2021-5683-0951019
FDA-CBER-2021-5683-0951020
FDA-CBER-2021-5683-0951021
FDA-CBER-2021-5683-0951022
FDA-CBER-2021-5683-0951023
FDA-CBER-2021-5683-0951024
FDA-CBER-2021-5683-0951025
FDA-CBER-2021-5683-0951026
FDA-CBER-2021-5683-0951027
FDA-CBER-2021-5683-0951028
FDA-CBER-2021-5683-0951029
FDA-CBER-2021-5683-0951030
FDA-CBER-2021-5683-0951031
83-0951032
FDA-CBER-2021-5683-0951033
FDA-CBER-2021-5683-0951034
FDA-CBER-2021-5683-0951035
FDA-CBER-2021-5683-0951036
FDA-CBER-2021-5683-0951037
FDA-CBER-2021-5683-0951038
FDA-CBER-2021-5683-0951039
FDA-CBER-2021-5683-0951040
FDA-CBER-2021-5683-0951041
FDA-CBER-2021-5683-0951042